Project: Sensitive Screening in Treatment of Skin Cancer

We will improve companion diagnostics and monitoring of acquired drug resistance of malignant melanoma (MM) patients, ensuring better response to treatment and reducing use of inefficient therapies. This will be accomplished using our proprietary DNA platform, product development and clinical experiences. The resulting CE certified products will be included in a workflow with a DNA extraction platform and co-marketed by large biotech Promega and tested by end-users on >300 patient samples.

Acronym SensiScreen Skin (Reference Number: 10440)
Duration 01/10/2016 - 01/10/2019
Project Topic Biological Sciences / Technologies
Network Eurostars 2
Call Eurostars Cut-Off 5

Project partner

Number Name Role Country
24071 PentaBase Coordinator Denmark
24072 Danish Technological Institute Partner Denmark
24073 Istituto Cantonale di Patologia Partner Switzerland